| [1] |
Chang CH, Tsai CK, Tsai TA, et al. Epidemiology, and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan[J]. Pediatr Neonatol, 2021, 62(5): 536-542. DOI: 10.1016/j.pedneo.2021.05.017.
|
| [2] |
Krafft C, Christy C. Mycoplasma pneumonia in children and adolescents[J]. Pediatr Rev, 2020, 41(1): 12-19. DOI: 10.1542/pir.2018-0016.
|
| [3] |
Wang X, Li M, Luo M, et al. Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020[J]. Emerg Microbes Infect, 2022, 11(1): 1508-1517. DOI: 10.1080/22221751.2022.2078228.
|
| [4] |
|
| [5] |
Li F, Zhang Y, Shi P, et al. Mycoplasma pneumoniae and adenovirus coinfection cause pediatric severe community-acquired pneumonia[J]. Microbiol Spectr, 2022, 10(2): e0002622. DOI: 10.1128/spectrum.00026-22.
|
| [6] |
|
| [7] |
Sheng CQ, Yang CF, Ao Y, et al. Mycoplasma pneumoniae pneumonia with pulmonary embolism: a study on pediatric cases in Jilin province of China[J]. Exp Ther Med, 2021, 21(3): 201. DOI: 10.3892/etm.2021.9634.
|
| [8] |
Han C, Zhang T, Zheng J, et al. Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study[J]. Ital J Pediatr, 2022, 48(1): 153. DOI: 10.1186/s13052-022-01344-0.
|
| [9] |
|
| [10] |
Leng J, Yang Z, Wang W. Diagnosis and prognostic analysis of Mycoplasma pneumoniae pneumonia in children based on high-resolution computed tomography[J]. Contrast Media Mol Imaging, 2022, 1985531. DOI: 10.1155/2022/1985531.
|
| [11] |
Wang X, Lin X. Analysis of clinical related factors of severe Mycoplasma pneumoniae pneumonia in children based on imaging diagnosis[J]. Comput Math Methods Med, 2022, 4852131. DOI: 10.1155/2022/4852131.
|
| [12] |
|
| [13] |
|
| [14] |
Li H, Li T, Cai Q, et al. Development and validation of a radiomics nomogram for differentiating Mycoplasma pneumonia and bacterial pneumonia[J]. Diagnostics (Basel), 2021, 11(8): 1330. DOI: 10.3390/diagnostics11081330.
|
| [15] |
Chen X, Li W, Wang F, et al. Early recognition of necrotizing pneumonia in children based on non-contrast-enhanced computed tomography radiomics signatures[J]. Transl Pediatr, 2021, 10(6): 1542-1551. DOI: 10.21037/tp-20-241.
|
| [16] |
Li S, Jiang W, Huang J, et al. Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor[J]. Eur Respir J, 2020, 56(6): 2002060. DOI: 10.1183/13993003.02060-2020.
|
| [17] |
Li J, Sun L, Wu X, et al. Early diagnosis of Mycoplasma pneumoniae in children: simultaneous amplification and testing (SAT) is the key[J]. Front Pediatr, 2019, 7: 441. DOI: 10.3389/fped.2019.00441.
|
| [18] |
Dai FF, Liu FQ, Chen X, et al. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. J Clin Pharm Ther, 2021, 46(3): 705-710. DOI: 10.1111/jcpt.13331.
|
| [19] |
Ahn JG, Cho HK, Li D, et al. Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and Meta-analysis[J]. BMC Infect Dis, 2021, 21(1): 1003. DOI: 10.1186/s12879-021-06508-7.
|
| [20] |
Shen HX, Liu C, Lin HJ, et al. The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a Meta-analysis[J]. Ital J Pediatr, 2022, 48(1): 176. DOI: 10.1186/s13052-022-01362-y.
|
| [21] |
Sun LL, Ye C, Zhou YL, et al. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Pediatr Infect Dis J, 2020, 39(3): 177-183. DOI: 10.1097/INF.0000000000002529.
|
| [22] |
|
| [23] |
Chen N, Li M. Case report and literature review: clinical characteristics of 10 children with Mycoplasma pneumoniae-induced rash and mucositis[J]. Front Pediatr, 2022, 10: 823376. DOI: 10.3389/fped.2022.823376.
|
| [24] |
Daba M, Kang PB, Sladky J, et al. Intravenous immunoglobulin as a therapeutic option for Mycoplasma pneumoniae encephalitis[J]. J Child Neurol, 2019, 34(11): 687-691. DOI: 10.1177/0883073819854854.
|
| [25] |
|
| [26] |
Jiang Z, Li S, Zhu C, et al. Mycoplasma pneumoniae infections: pathogenesis and vaccine development. pathogens[J]. Pathogens, 2021, 10(2): 119. DOI: 10.3390/pathogens10020119.
|